A new study led by Stephen D. Nimer, M.D., director of Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, shows how a key molecule regulates the ...

A person's lifetime risk for cancer may begin before they are even born, reports a paradigm-shifting study by Van Andel Institute scientists. The findings, published in Nature Cancer, identified two ...

The role of epigenetic mechanisms in cancer has gained interest in recent studies. The reversible nature of epigenetic changes on genomic DNA and histones holds promise for the development of ...

Investigators constructed weighted methylation risk scores to pinpoint specific risk factors associated with early-onset CRC versus late-onset CRC.

A pair of medications that make malignant cells act as if they have a virus could hold new promise for treating colorectal cancers and other solid tumors, reports a new study. The preclinical research ...

Drs. Pallabi Mustafi and Ruben Raychaudhuri at Fred Hutch Cancer Center recently received Young Investigator Awards from the ...

Scientists say they have found a pattern of so-called epigenetic 'marks' in a transition state between normal and pancreatic cancer cells in mice, and that the normal cells may keep at least a ...

A pair of epigenetic cancer drugs packs a “one-two punch” against colorectal tumors to knock them out more effectively than either medication alone, a new study in cells suggests. In a journal article ...

Epigenome remodeling, including widespread changes to DNA methylation and 3D chromatin structure, is increasingly recognized as an important mechanism of gene deregulation in cancer. For example, at ...

Epigenetics play a significant role in cancer onset and spread, and scientists explore epigenetic regulators for their roles in carcinogenesis. In this webinar brought to you by The Scientist, Özgen ...

The role of epigenetic mechanisms, such as DNA or RNA methylation, histone modifications, nucleosome changes, and non-coding RNAs in cancer has gained increasing interest in recent studies. The ...

A new preclinical study by Van Andel Institute Professor Dr. Scott Rothbart and colleagues reveals how two epigenetic cancer medications approved for separate uses may hold promise for treating ...